News2 mins ago
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
– Highly statistically significant and clinically meaningful results – – 63% mean blood Phe reduction in primary analysis population (p<0.0001) – – Conference call and webcast...
